Molecules with potent anti-leishmanial activity play a crucial role in identifying treatments for leishmaniasis and aiding in the design of novel drugs to combat the disease, ultimately protecting individuals and populations. Various methods have bee...
BACKGROUND: Cutaneous leishmaniasis (CL) is a parasitic disease caused by protozoan parasites of the genus Leishmania, leading to significant morbidity in endemic regions. While effective, traditional diagnostic methods often suffer from limitations ...
Leishmaniasis is a poverty-related disease endemic in 98 countries worldwide, with morbidity and mortality increasing daily. All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit several drawbacks including to...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.